IL6 and multiple sclerosis: B-cell depletion treatment normalizes BSF-2(IL-6) levels produced by multiple sclerosis patients’ B cells, and patients who respond well to B-cell depletion treatment, over an extended period of time, experience a “reset” in their auto-immune condition-related CSIF:TGIF(IL-10) levels’ deficiency, with their re-populated B cells directed towards convenient CSIF:TGIF(IL-10) production [47,48].